Biogen. has been granted a patent for a method to assess the risk of Progressive multifocal leukoencephalopathy (PML) in Multiple Sclerosis patients. The method involves detecting JC Virus antibodies in biological samples and administering anti-VLA-4 therapy based on the assay results. GlobalData’s report on Biogen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Biogen, Personalized cancer vaccines was a key innovation area identified from patents. Biogen's grant share as of July 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Assessing pml risk in multiple sclerosis patients
The patent US12066442B2 outlines a method for treating patients with Multiple Sclerosis (MS) by assessing the presence of JC Virus (JCV) antibodies in biological samples. The method involves a multi-step assay that begins with the formation of a reaction mixture containing the patient's sample and highly purified viral-like particles (HPVLP). The assay detects the level of anti-JCV antibodies, using a labeled detection reagent, and establishes a threshold for classification as negative based on the inhibition of unbound antibodies. The method specifies various parameters, including sample types (serum, urine, plasma, blood, or cerebrospinal fluid), dilution ratios, and incubation times, to ensure accurate results.
Additionally, the patent details the conditions under which anti-VLA-4 therapy, specifically natalizumab, may be administered. It emphasizes the importance of acquiring assay results before and after treatment, as well as monitoring the patient's treatment history with non-anti-VLA-4 immunosuppressants. The method also includes guidelines for periodic assessment of anti-JCV antibody levels, with an increase indicating a heightened risk of developing progressive multifocal leukoencephalopathy (PML). Overall, the claims provide a comprehensive framework for the safe and effective treatment of MS patients, integrating diagnostic and therapeutic strategies.
To know more about GlobalData’s detailed insights on Biogen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
